RxDoctor Payments Data

Michael Adenaike, MD

Cardiovascular Disease · Doylestown, PANPI 1700049939

Payments from drug & device makers

$14,198in general payments, 2019–2025

Across 200 payments — averaging $70.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$11K
  • Novartis$783
  • Merck$481
  • Boehringer Ingelheim$237
  • E.r. Squibb & Sons, L.L.C.$227
  • Pfizer$219
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$10,36473%
  • Travel & lodging$1991%
  • Food & beverage$3,62326%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,198 in reported general payments places this provider in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$178,986
Medicare patients
1,171
Services billed
2,748

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban443$471,951
XareltoRivaroxaban118$141,340
JardianceEmpagliflozin62$64,839
EntrestoSacubitril/Valsartan47$50,024
FarxigaDapagliflozin Propanediol32$29,385
Repatha SureclickEvolocumab22$25,706
MultaqDronedarone Hcl12$15,618
Dofetilide38$10,540
Metoprolol Succinate584$9,994
Fenofibrate40$8,148
Atorvastatin Calcium560$7,110
Ezetimibe286$6,427
Diltiazem 24hr Er (Cd)Diltiazem Hcl173$4,619
Valsartan97$3,645
Rosuvastatin Calcium265$3,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$219$471,951443 claims
Johnson & JohnsonXarelto$11,017$141,340118 claims
Boehringer IngelheimJardiance$237$64,83962 claims
NovartisEntresto$783$50,02447 claims
AstraZenecaFarxiga$204$29,38532 claims
Sanofi-aventis U.S. LLCMultaq$107$15,61812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Doylestown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →